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14:273–279, 2013.—Increased pulmonary artery pressure is a well-known phenomenon of hypoxia and is seen
in patients with chronic pulmonary diseases, and also in mountaineers on high altitude expedition. Different
mediators are known to regulate pulmonary artery vessel tone. However, exact mechanisms are not fully
understood and a multimodal process consisting of a whole panel of mediators is supposed to cause pulmonary
artery vasoconstriction.
We hypothesized that increased hypoxemia is associated with an increase in vasoconstrictive mediators and
decrease of vasodilatators leading to a vasoconstrictive net effect. Furthermore, we suggested oxidative stress
being partly involved in changement of these parameters.
Oxygen saturation (Sao2) and clinical parameters were assessed in 34 volunteers before and during a Swiss
research expedition to Mount Muztagh Ata (7549m) in Western China. Blood samples were taken at four
different sites up to an altitude of 6865m.
A mass spectrometry-based targeted metabolomic platform was used to detect multiple parameters, and re-
vealed functional impairment of enzymes that require oxidation-sensitive cofactors. Specifically, the tetra-
hydrobiopterin (BH4)-dependent enzyme nitric oxide synthase (NOS) showed significantly lower activities
(citrulline-to-arginine ratio decreased from baseline median 0.21 to 0.14 at 6265m), indicating lower NO
availability resulting in less vasodilatative activity. Correspondingly, an increase in systemic oxidative stress was
found with a significant increase of the percentage of methionine sulfoxide from a median 6% under normoxic
condition to a median level of 30% ( p < 0.001) in camp 1 at 5533m. Furthermore, significant increase in vaso-
constrictive mediators (e.g., tryptophan, serotonin, and peroxidation-sensitive lipids) were found.
During ascent up to 6865m, significant altitude-dependent changes in multiple vessel-tone modifying mediators
with excess in vasoconstrictive metabolites could be demonstrated. These changes, as well as highly significant
increase in systemic oxidative stress, may be predictive for increase in acute mountain sickness score and
changes in Sao2.
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Introduction
High altitude stay may lead to acute mountain sick-ness (AMS), high altitude cerebral edema (HACE), and
high altitude pulmonary edema (HAPE). Under hypoxic
conditions, physiologically appearing pulmonary vasocon-
striction is overwhelming in subjects with HAPE, suggesting
exaggerated hypoxic pulmonary vasoconstriction (HPV) be-
ing the main trigger for developing HAPE (Maggiorini et al.,
2001). Different metabolic pathways have been suggested to
cause HPV and pulmonary hypertension.
The nitric oxide (NO) pathway is assumed to be one of the
key regulators of the pulmonary artery vessel tone. Dimin-
ished bioavailability of the vasorelaxant NO may appear di-
rectly through reactive oxygen species (ROS), or secondary
due to dysregulation of the underlying L-arginine metabo-
lism, or diminished expression or activation of NOS
(Forstermann, 2010). Symmetric and asymmetric dimethy-
larginine (SDMA and ADMA), which are known as a car-
diovascular risk factors, compete with L-arginine for
transportation into cells, thus reducing the substrate for NO
synthesis (Vallance et al., 1992; MacAllister et al., 1996; Lluch
et al., 2006). Furthermore, arachidonic and linoleic acids
products (e.g., hydroxy-eicosatetranoic acids (HETE), pros-
taglandins, and leukotrienes) are determinants in the regula-
tion of the vascular tone and possibly contribute to
pulmonary hypertension (Ma et al. 2011; Chawengsub et al.,
2009). In particular, serotonin has been shown to increase
pulmonary artery pressure in hypoxia (Morecroft et al., 2007),
partially in consequence of ROS-dependent generation of the
transporter, providing serotonin to the site of action, has been
demonstrated (Lawrie et al., 2005).
ROS may be involved in development of HPV and pul-
monary hypertension due to diverse mechanisms, either by
the above mentioned disruption in the NO-pathway, by in-
teraction with the endothelial layer, or by uncoupling of oxi-
dases, such as xanthine oxidase and nicotinamide adenine
dinucleotide phosphate oxidase (Demarco et al., 2010 ; Jerkic
et al., 2011 ; Lane et al., 2011). Because of their short half lives,
quantification of ROS is difficult and requires special meth-
odological settings. Nevertheless, the biochemical conse-
quences of ROS can be readily detected by measuring the
levels of intermediary metabolites altered by oxidative stress.
These intermediate metabolites include polyunsaturated fatty
acids (PUFA), such as linoleic acid or arachidonic acid, which
can be oxidized to hydroxy-octadecadienoic acid (HODE) or
hydroxy-eicosatetraenoic acid (HETE), respectively. Further-
more, under oxidative stress, prostaglandins and thrombox-
anes are produced from arachidonic acid over cyclooxygenase
(Yoshida et al., 2006; Niki, 2008). In addition, amino acids
such as methionine and tyrosine are oxidized to methionine
sulfoxide (Vogt, 1995) and changes in enzyme products de-
pending on ROS-sensitive cofactors may be used as markers
of oxidative stress.
High altitude stay serves as a valuable model to investigate
isolated effects of hypoxia, without the limitations of the most
clinical studies investigating conditions with severe hypox-
emia (e.g., critically ill patients), where there are many con-
founding factors such as multiple co-morbidities.
Furthermore, most of our knowledge results from in vitro or
animal studies, which might not reflect the real human
pathway changes. We, therefore, hypothesized that progres-
sive hypobaric hypoxia leads to changes in multiple vessel
tone-modifying mediators with increase in metabolites with
vasoconstrictive properties, paralleled by a decrease in me-
tabolites with vasodilatatory effects, and that some of these
pathway changes might be induced primarily by oxidative
stress (Goodacre et al., 2004; Wishart et al., 2007; Gomase
et al., 2008).
Methods
Study participants
Thirty-four healthy volunteers, aged between 29 and 65
years (mean 46 years), including 7 female participants, were
examined during a high altitude expedition in 2005 to Mount
Muztagh Ata (7545m) in Western China. The design of the
expedition was such that no strenuous physical exercise was
necessary to accomplish the route. During the expedition,
ample resting days allowing for good adaptation were
scheduled to reduce the variables tested to those primarily
involving hypobaric hypoxia rather than those due to ex-
hausting exercise or exposure to heat or cold. The study was
approved by the cantonal ethics board of Zurich (KEK-Nr.
1189) and is in accordance with the Declaration of Helsinki.
All participants provided written informed consent.
Study design and blood samples
Medical testing, including blood sampling, clinical exami-
nation and assessment of AMS-scores, was performed first in
Zu¨rich at 490m/1474 ft (baseline examination). After air tra-
vel to Islamabad, Pakistan (500m), the journey continued by
bus to Subash, China (3730m), where the expedition started
(day 1). The examinationswere repeated at base camp (4497m
above sea level) on day 3, at camp 1 (5533m) on day 6, at camp
2 (6265m) on day 13, and at camp 3 (6865m) on day 19. To
determine AMS, different scoring systems, such as the Lake
Louise Score (LLS) and the environmental symptoms ques-
tionnaire cerebral score (AMS-C), were used (Roach, 1993).
We used 20-gauge butterfly cannulas (Becton Dickinson,
Basel, Switzerland) and sterile tubes (Sarstedt AG, Sevelen,
Switzerland) for collecting serum and citrated plasma. The
blood drawings were done within 10min in a standardized
fashion. After centrifugation at 2300 g at the site (Rotanta,
Hettich AG, Ba¨ch, Switzerland), the supernatants were
aliquoted into prelabeled tubes and immediately frozen at
£ - 20C in a Peltier-element freezer. The samples were kept
frozen until analysis in the laboratories.
Laboratory testing
AbsoluteIDQ p150 KIT plates (Biocrates Life Sciences
AG, Innsbruck, Austria) were used according to the manu-
facturer’s instructions for quantifying amino acids, acylcar-
nitines, phosphatidylcholines, hexoses, and biogenic amines
(e.g., dimethylarginine, serotonin) using an API 4000 QTrap
mass spectrometer (AB Sciex, Toronto) with electrospray
ionization. After extraction, prostaglandins and other PUFA
were analyzedby reverse phaseHPLC-ESI-MS/MS innegative
MRM detection mode using an API 4000 QTrap mass spec-
trometer (WO/2008/145384). Three groups of PUFA products
were analyzed: the ROS-generated (i.e., nonenzymatic, linoleic
acid derivatives (– )9-hydroxy-10E,12Z-octadecadienoic acid
[9-HODE], and 13(S)-hydroxy-9Z,11E-octadecadienoic acid
[13S-HODE]), the arachidonic acid-derived lipoxygenase
products (12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid
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[12S-HETE], 15(S)- hydroperoxy-5Z,8Z,11Z,13E-eicosate-
traenoic acid [15S-HpETE], and 15(S)-hydroxy-5Z,8Z,11Z,13E-
eicosatetraenoic acid [15S-HETE]), and the cyclooxygenase
products (prostaglandins D2 and E2 [PGD2 and PGE2] and
leukotriene B4 [LTB4]). C- reactive protein (CRP) concentra-
tions in plasma were determined on a Dimenson Vista Ana-
lyzer 1500 (Siemens, Marburg, Germany) using a routine
turbidimetric immunoassay. Osmolality measurements were
performed on a routine freezing point osmometer OsmoLab
One/16S (LLA Instruments, Berlin, Germany) in a standard-
ized fashion (ISO15189).
Statistical methods
The data were assessed by a principal component analysis
and a discriminant analysis incorporated in MarkerView
Software (AB Sciex, Toronto). The dataset used for this study
has been chosen due to its relevance to the topic and not due to
a statistical procedure. Therefore, analysis was done using a
Friedman repeated measures ANOVA on ranks and Mann-
Whitney tests. Statistical software R version 2.8.1, SPSS Sta-
tistics, Version 17.0 (IBM, USA), as well as MetIDQ Stat Pack
(Biocrates Life Sciences AG, Innsbruck, Austria) and Graph-
Pad Prism (GraphPad Software, La Jolla, CA). Results are
expressed as the median with interquartile range, and all box
plots were drawn using Sigma Plot software version 10 with
standard settings.
Results
Course of the expedition and standard
laboratory parameters
Nineteen of 34 participants reached the summit of Mount
Muztagh Ata (7545m), which corresponds to a quite good
success rate of 55.8%. Mild to moderate AMS, corresponding
to a AMS score > 3 was seen in 8/34 at base camp, in 9/34 at
camp 1, in 9/33 at camp 2, and in 2/18 at camp 3. In camp 2
and 3, the study population was reduced due to premature
return, either because of more severe AMS symptoms or be-
cause of exhaustion. Additionally, blood sampling was lim-
ited at camp 3 because of adverse weather conditions. AMS
scores increased with altitude, whereas Sao2 decreased over
the altitude and time (Table 1).
During routine laboratory testing of the samples, no he-
molysis or clots were found, and osmolalities were within the
normal range (280–310mosm/L, data not shown) were
found. Samples were also tested for lipemia or icteria and
were found to be negative. The sample quality could be fur-
ther reassured by the good correlation of creatinine levels
measured with a Jaffe-based method on a routine analyzer
compared with creatinine results obtained by mass-spec-
trometry. Increase in lipoxygenase products, paralleled by
low levels of cycloxygenase products over the altitude, are
consistent with the broad use of nonsteroidal anti-inflamma-
tory drugs and also reflect good preanalytic quality. Routine
laboratory testing revealed a mild inflammatory response with
increase in median CRP values from 0.4mg/L, interquartile
range (0.4–1.0) at base line to 9.8mg/L (4.1–22.3) at base camp,
to 7.5mg/L (3.4–20.0) at camp 1, 2.2mg/L (1.5–84.2) at camp 2,
and 1.9mg/L (1.5–2.7) at camp 3. Lactate levels were only
mildly elevated (< 2.5mmol/L) (data not shown).
Oxidative parameters
Lipid oxidation. In normoxic serum, only 15S-HETE was
present in quantifiable amounts, while the highly reactive
hydroperoxide intermediate 15S-HpETE was below the limit
of detection. All lipid peroxidation products were signifi-
cantly increased under hypobaric conditions ( p< 0.001). Fig-
ure 1 shows that PUFA increase up to a height of 5500m and
level off thereafter.
Methionine sulfoxidation. The amount of methionine
sulfoxide (MetSO) determined in relation to methionine, a
surrogate marker for oxidative stress, increased significantly
from median 6% under normoxic conditions to 15% at base
camp (4497m) and peaked at 30%under hypobaric conditions
in camp 1 (5533m; p < 0.001). With further ascent, the median
values decreased but remained high (20% methionine sul-
foxidation) (Fig. 2).
Tetrahydrobiopterin-dependent enzyme activities. At
baseline examination, the median phenylalanine plasma
concentration was 84 lmol/L (75–98), and the median tyro-
sine concentration was 68 lmol/L (51–86), resulting in a ty-
rosine-to-phenylalanine ratio of 0.81 (0.70–0.91). At high
altitudes, the median phenylalanine concentration increased
significantly to 115lmol/L (97–132) at base camp (4497m),
and with further climbing, reached 125 lmol/L (111–145) at
6865m. Conversely, median tyrosine plasma concentrations
remained nearly constant or slightly decreased, up to an al-
titude of 5533m. In camps 2 (6265m) and 3 (6865m), tyrosine
increased slightly to 78lmol/L (62–102) and 87 lmol/L (76–
103), respectively. The different altitude-dependent concen-
tration changes of the two amino acids were reflected by
significantly lowered tyrosine-to-phenylalanine ratios. The
Table 1. Data Supply for Expedition Course and Incidence and Severity of Acute Mountain Sickness
Base line Base camp Camp 1 Camp 2 Camp3
Altitude (m) 490 4497 5533 6265 6865
Day 3 6 13 19
Subjects included 34/34 34/34 34/34 33/34 18/34
Subjects with acute
mountain sickness
0/34 (0%) 8/34 (23.5%) 9/34 (26.5%) 9/33 (27.3%) 2/18 (11.1%)
AMS Score, median 0 2 2 1 1
AMS Score, min 0 0 0 0 0
AMS Score, max 0 5 5 7 4
SaO2, mean 99.6% 83.9% 75.5% 73.3% 74.5%
P values < 0.001 < 0.001 < 0.001 < 0.001
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ratio decreased to 0.62 (0.55–0.68) at 4497m and 0.55
(0.50–0.64) at 5533m above sea level. With further climbing,
tyrosine-to-phenylalanine ratios increased again, but did
not return to base level. Under hypobaric conditions, the
citrulline-to-arginine ratio decreased significantly reflecting
reduced NO generation (Fig. 3).
Symmetric and asymmetric dimethylarginine. The levels
of ADMA did not significantly change between the different
heights (data not shown). However, the concentrations of
SDMA exhibited significant changes ( p= 0.023): 0.39 lmol/L
(0.0–0.53) before expedition, 0.61 lmol/L (0.34–0.69) at base
camp, 0.60 lmol/L (0.09–0.76) at camp 1, 0.69 lmol/L (0.10–
0.84) at camp 2, and 0.65 lmol/l (0.38–0.80) at camp 3.
Tryptophan and serotonin. The levels of tryptophan ex-
hibited significant changes ( p< 0.001):medianvalue 65lmol/L
(55–72) before expedition, 73 lmol/L (58–84) at base camp,
72 lmol/L (59–86) at camp 1, 85 lmol/L (69–105) at camp 2,
and 108 lmol/L (71–129) at camp 3. The concentrations of
serotonin also showed significant changes ( p = 0.001): median
value 0.68 lmol/L (0.49–0.96) before expedition, 0.78 lmol/L
(0.69–1.21) at base camp, 0.94 lmol/L (0.51–1.25) at camp 1,
1.10 lmol/L (0.57–1.64) at camp 2, and 1.10 lmol/L (0.69–
1.38) at camp 3 (Fig. 4).
Clinical parameters in correlation with marker of oxidative
stress and vessel-tone modifying mediators
Regression analysis was done for clinical parameters such
as AMS-score and SaO2 with above mentioned parameters.
Levels of MetSO, citrulline-to-arginine ratio, 15S-HpETE, 9-
HODE, and 13S-HODE appeared to be significant predictors
for the level of AMS score obtained, as well as for changes in
Sao2 (Fig. 5). In contrast, regression analysis did not show a
significant result for other parameters, for example, serotonin,
tryptophan, ADMA, or SDMA (results not shown).
Discussion
The most potent vasodilator NO results from the conver-
sion of arginine to citrulline. The quantitative assessment of
the product-to-substrate ratios such as tyrosine-to-phenylal-
anine (for PAH) and citrulline-to-arginine (for NOS) is useful
to measure NO generation. For PAH and for NOS tetra-
hydropterin (BH4), an essential cofactor is needed. As BH4 is
quickly oxidized under hypoxic conditions, it is no longer
available at appropriate conditions to maintain the activity of
PAH and NOS. The decreased citrulline-to-arginine ratio
found in this study therefore reflects diminished endogenous
NO generation, which might be explained by increase in ox-
idative stress with increasing altitude. Beside this indicator of
oxidative stress, methionine sulfoxidation serves as a lipid-
independent indicator of oxidative stress. The values of me-
thionine sulfoxide obtained in the present study were even
higher than those found under severe clinical conditions.
Patients with septicemia and end stage renal disease (ESRD)
FIG. 1. Increasing PUFA (per-)oxidation at high altitude.
Even the highly reactive, short-lived 15S-HpETE could be
detected at significantly elevated concentrations.
FIG. 2. Increased methionine sulfoxidation, given as the
ratio of methionine sulfoxide to methionine (MetSO/Met), as
a lipid-independent marker of oxidative stress.
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were characterized by elevated oxidative stress levels, with
methionine sulfoxidation reaching a median of 16% in ESRD
(WO 2010/139341) and a 20% in a mixed sepsis cohort (un-
published data) compared to our findings with significant
higher median levels of 30% at camp 1 (5,533m). Together
with the increase of PUFA oxidation products (i.e., ROS-
generated linoleic acid derivates and arachidonic acid-
products), these results strongly suggest relevant systemic
generation of ROS in vivo.
There is controversy regarding whether ROS contribute to
high altitude-related diseases, especially HAPE and HACE
(Araneda et al., 2005; Bailey et al., 2009). It is known that ROS
directly increases vascular permeability (Lee et al., 2006). As
shown, our results suggest ROS-dependent decrease in NO
availability under hypobaric hypoxia. Of course, other me-
diators could be involved as well. In agreement, other studies
have shown that a lack of NO (which has vasorelaxant
properties in the pulmonary arteries) may also contribute to
endothelial dysfunction, especially in pulmonary hyperten-
sion-inducedHAPE (Bailey et al., 2010). In addition, we found
significant increase in ROS-dependent 15-HETE and 12-
HETE, which both are known to have vasoconstrictive
properties (Burhop et al., 1988; Nishiyama et al., 1998; Yiu
et al., 2003). The essential amino acid tryptophan, the biogenic
amines serotonin, and SDMA, which all are supposed to have
vasoconstrictive function in pulmonary vessels, also in-
creased significantly during the high altitude stay. This pat-
tern of metabolites may be partially responsible for the
development of physiological hypoxic pulmonary vasocon-
striction.
Sao2 decreases with reduced barometric pressure by re-
duced oxygen tension pressure. Sao2 might have a more
pronounced decline as HPV leads to increased ventilation/
perfusion mismatch. This hypothesis is supported by the re-
sults of the regression analysis, pursuant to which metabo-
lites with potential net-vasoconctricitve effect (e.g., MetSO,
citrulline-to-arginine ratio, 15S-HpETE, and 13-HODE)
showed to be possible predictors for changes in AMS score
and SaO2 (Fig. 5). Although it is well accepted that (hypo-
baric) hypoxia leads to increase in pulmonary artery pressure,
further investigations are needed to clarify whether these
findings not only correlate but also are causative with increase
in pulmonary artery pressure or development of HAPE
(Duplain et al., 2000; Sylvester et al., 2012). As prolonged
exposure to hypobaric hypoxia serves as a pathophysiologic
model in critically ill patients or patients with pulmonary
diseases, additional investigations are needed to clarify rele-
vance of ROS and examined mediators in disease progression
or extensive hypoxic pulmonary vasoconstriction. Moreover,
the potential role of ROS-targeted therapy in the prevention of
hypoxic pulmonary vasoconstriction and pulmonary hyper-
tension needs further attention.
The main limitation of this study is the lack of surrogate
markers of pulmonary vasoconstriction (e.g., echocardio-
graphic and pressure measurements). The relatively small
cohort size, although from our knowledge this is the biggest
cohort size in the setting of a high altitude expedition where
FIG. 3. Inhibition of BH4-dependent enzymes as a consequence of oxidative stress (NO synthase, left, and phenylalanine
hydroxylase, right). Decrease in the citrulline-to-arginine ratio signifies diminished NO availability.
FIG. 4. Significant increase in serotonin and, more pro-
nounced, in its precursor tryptophan, which are both known
to have vasoconstrictive properties.
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measurements have been done up to 6865m, limits the final
conclusion. The selection of the fittest and least affected sub-
jects in the higher camps might explain the recurrent pattern
of metabolic changes with leveling off over the altitude and
time. This statement is supported by the recovery of Sao2 at
camp 3 and by the relatively low percentage of AMS-affected
subjects at higher altitude (Table1). Therefore, statements on
how severe AMS or HAPE are influenced by oxidative stress
are sparse. The results reflect more the usual adaption to hy-
pobaric hypoxia, as none of the subjects suffered from severe
AMS. In respect to the limited amount of blood samples that
can be drawn, the difficult and complicated research setting
during a high altitude expedition, and the multiple pathways
that may be involved in the development of hypoxic pulmo-
nary vasoconstriction, mass spectrometry-based analysis of
metabolic changes offers a specific and sensitive approach
and further enables to detect possible escape phenomenons.
This field study is the first study focusing on oxidative
stress-related changes with a multi-level approach in humans
at extreme altitude. Our results show multiple, significant
altitude-dependent changes in hypoxia-related metabolites
with domination of vasoconstrictive net effect. Our results
suggest increased concentration of vasoconstrictive metabo-
lites being associated with increase in AMS score and
worsened oxygenation. This novel approach extends the un-
derstanding of hypoxia-related mechanisms on a biochemical
level. Further studies are required to confirm vascular dys-
regulation as a result of biochemical pathway alteration
shown.
In conclusion, we describe the effects of hypobaric hypoxia
during high altitude trekking and mountaineering. Our re-
sults suggest pronounced systemic oxidative stress under
hypoxic conditions being correlated with changes in AMS
score and decreased Sao2. In addition, we demonstrate sig-
nificant changes in multiple biochemical pathways with va-
soconstrictive properties. This novel approach extends the
understanding of hypoxia-related mechanisms on a bio-
chemical level. Further studies are required to confirm vas-
cular dysregulation as a result of biochemical pathway
alteration shown.
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